Skip to main content
. 2022 Nov;10(22):1228. doi: 10.21037/atm-22-5352

Figure 3.

Figure 3

Median IC-PFS times of pyrotinib and radiotherapy vs. pyrotinib-based therapy for patients with active brain metastasis in the 2 groups. IC-PFS, intracranial progression-free survival; HR, hazard ratio; CI, confidence interval.